Ashley Winslow is Chief Executive Officer and Chief Scientific Officer of Odylia Therapeutics, a nonprofit biotech focused on accelerating drug development for rare diseases. Odylia develops therapeutics in collaboration with patient groups and a strategic network of CROs, academic partners, and industry, with the aim of bringing life changing therapeutics to patients.
Ashley received her PhD in Medical Genetics from the University of Cambridge and completed her postdoctoral work at Massachusetts General Hospital and Harvard Medical School. Before joining Odylia, Ashley worked in the Precision Medicine and Human Genetics and Computational Biomedicine group at Pfizer and the Orphan Disease Center at the University of Pennsylvania. She has experience overseeing drug development from target discovery to early phase clinical programs and brings to Odylia more than 15 years of drug development experience in academic, industry, and non-profit sectors. Ashley serves on the International Angelman Syndrome Research Council (INSYNC-AS), CHAMP1 Scientific Advisory Board, Innovative Genomics Institute (IGI) Affordability Task Force, and the RARE-X/ Global Genes Scientific Advisory Board.
